Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm.

ABSTRACT: High-quality health care not only includes timely access to effective new therapies but timely abandonment of therapies when they are found to be ineffective or unsafe. Little is known about changes in use of medications after they are shown to be ineffective or unsafe. In this study, we examine changes in use of two medications: fenofibrate, which was found to be ineffective when used with statins among patients with Type 2 diabetes (ACCORD lipid trial); and dronedarone, which was found to be unsafe in patients with permanent atrial fibrillation (PALLAS trial). We examine the patient and provider characteristics associated with a decline in use of these medications. Using Medicare fee-for-service claims from 2008 to 2013, we identified two cohorts: patients with Type 2 diabetes using stat

SUBMITTER: Smith LB 

PROVIDER: S-EPMC7725279 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature